Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation.
Couch JA, Zhang G, Beyer JC, de Zafra CL, Gupta P, Kamath AV, Lewin-Koh N, Tarrant J, Allamneni KP, Cain G, Yee S, Ross S, Cook R, Tsai SP, Ruppel J, Ridgway JB, Paluch M, Hass PE, Franklin J, Yan M. Couch JA, et al. Among authors: beyer jc. Clin Cancer Res. 2016 Mar 15;22(6):1469-79. doi: 10.1158/1078-0432.CCR-15-1380. Epub 2015 Nov 20. Clin Cancer Res. 2016. PMID: 26589434
Chronic DLL4 blockade induces vascular neoplasms.
Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K, Plowman GD. Yan M, et al. Among authors: beyer jc. Nature. 2010 Feb 11;463(7282):E6-7. doi: 10.1038/nature08751. Nature. 2010. PMID: 20147986
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade.
Lin WY, Gong Q, Seshasayee D, Lin Z, Ou Q, Ye S, Suto E, Shu J, Lee WP, Lee CW, Fuh G, Leabman M, Iyer S, Howell K, Gelzleichter T, Beyer J, Danilenko D, Yeh S, DeForge LE, Ebens A, Thompson JS, Ambrose C, Balazs M, Starovasnik MA, Martin F. Lin WY, et al. Blood. 2007 Dec 1;110(12):3959-67. doi: 10.1182/blood-2007-04-088088. Epub 2007 Aug 8. Blood. 2007. PMID: 17687108 Free article.
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, Ramakrishnan V, Kim AH, Beyer JC, Mason Shih L, Darbonne WC, Xin Y, Yu R, Xiang H, Brachmann RK, Weekes CD. Patnaik A, et al. Among authors: beyer jc. Cancer Chemother Pharmacol. 2014 May;73(5):951-60. doi: 10.1007/s00280-014-2426-8. Epub 2014 Mar 17. Cancer Chemother Pharmacol. 2014. PMID: 24633809 Clinical Trial.
48 results